serine palmitoyltransferase small subunit BGenealiases: ADMP · C3orf57 · SSSPTB
Q-omics provides the consensus-scored SPTSSB profile across patient tissues and cancer cell-line models. SPTSSB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPTSSB is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SPTSSB RNA expression shows 13,616 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where SPTSSB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTSSB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTSSB survival associations across molecular data types. SPTSSB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTSSB RNA expression–survival associations across cancer types. High SPTSSB expression shows unfavorable associations in KIRC, KIRP, UVM and LIHC, but favorable associations in SCLC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for SPTSSB RNA expression.
This table summarizes SPTSSB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SPTSSB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTSSB shows lower tumor expression in HNSC, KIRC, KICH, KIRP and STAD and higher tumor expression in LUSC. The HNSC box plot shows higher SPTSSB RNA expression in normal versus tumor tissue (log2 FC = −1.894, t-test p < 0.001).
This table shows molecular features associated with SPTSSB in patient tissues and cancer cell lines. In patient samples, SPTSSB shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTSSB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
